Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 07, 2023 07:31 ET | Source: Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics to Present at 2023 Wells Fargo Healthcare Conference

SAN CARLOS, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor...
August 18, 2023 17:00 ET | Source: Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SAN CARLOS, Calif., Aug. 18, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor...
August 08, 2023 16:01 ET | Source: Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics Reports Second Quarter and First Half 2023 Financial Results and Corporate Updates

FDA Priority Review of Biologics License Application (BLA) on Track for Lifileucel in Advanced Melanoma with Prescription Drug User Fee Act (PDUFA) Action Date of November 25, 2023 Preparing for...
July 25, 2023 16:01 ET | Source: Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics to Present Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Therapy at IASLC 2023 World Conference on Lung Cancer

SAN CARLOS, Calif., July 25, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor...
July 24, 2023 16:01 ET | Source: Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics to Host Second Quarter 2023 Financial Results Conference Call and Webcast on Tuesday, August 8, 2023

SAN CARLOS, Calif., July 24, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor...
July 21, 2023 17:34 ET | Source: Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SAN CARLOS, Calif., July 21, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor...
July 13, 2023 16:01 ET | Source: Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics Announces Closing of $172.5 Million Common Stock Public Offering

SAN CARLOS, Calif., July 13, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor...
July 10, 2023 21:46 ET | Source: Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics, Inc. Announces Pricing of Its Public Offering of $150 Million of Common Stock

SAN CARLOS, Calif., July 10, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (Nasdaq: IOVA) (“Iovance” or “Company”), a biotechnology company focused on innovating, developing, and delivering...
July 10, 2023 16:34 ET | Source: Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics, Inc. Announces Proposed Public Offering of Common Stock

SAN CARLOS, Calif., July 10, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (Nasdaq: IOVA) (“Iovance” or “Company”), a biotechnology company focused on innovating, developing, and delivering...
July 10, 2023 07:00 ET | Source: Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics Announces Regulatory and Clinical Updates for TIL Therapy in Advanced Non-Small Cell Lung Cancer

Positive FDA Feedback Supports IOV-LUN-202 Trial Design for Accelerated Approval of TIL Therapy in Post-Anti-PD-1 Advanced Non-Small Cell Lung Cancer (NSCLC) Preliminary Clinical Data in...